Nuveen LLC Buys New Shares in Bausch Health Cos Inc. $BHC

Key Points

• Nuveen LLC acquired a new stake in Bausch Health Cos Inc., purchasing 227,230 shares valued at approximately $1,473,000, representing a 0.06% ownership in the company.
• Director John Paulson significantly increased his shareholdings by 96.35%, acquiring 34,721,118 shares at an average price of $9.00, bringing his total ownership to about $636.8 million.
• Analyst ratings for Bausch Health Cos upgraded from "hold" to "buy", with a current consensus target price of $9.00.

Nuveen LLC bought a new position in Bausch Health Cos Inc. (NYSE:BHC - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 227,230 shares of the company's stock, valued at approximately $1,473,000. Nuveen LLC owned about 0.06% of Bausch Health Cos as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of Bausch Health Cos by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company's stock worth $76,152,000 after buying an additional 61,621 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Bausch Health Cos by 3.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,113,107 shares of the company's stock worth $25,089,000 after buying an additional 90,166 shares during the last quarter. Compass Rose Asset Management LP boosted its stake in shares of Bausch Health Cos by 366.7% in the 4th quarter. Compass Rose Asset Management LP now owns 2,100,000 shares of the company's stock worth $16,926,000 after buying an additional 1,650,000 shares during the last quarter. Private Management Group Inc. boosted its stake in shares of Bausch Health Cos by 13.8% in the 1st quarter. Private Management Group Inc. now owns 1,439,426 shares of the company's stock worth $9,313,000 after buying an additional 174,176 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Bausch Health Cos by 4.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,341,999 shares of the company's stock worth $8,700,000 after buying an additional 57,963 shares during the last quarter. Hedge funds and other institutional investors own 78.65% of the company's stock.

Bausch Health Cos Stock Performance

Shares of NYSE:BHC traded down $0.18 during trading on Thursday, hitting $7.18. 657,498 shares of the company were exchanged, compared to its average volume of 2,679,873. The company has a market cap of $2.66 billion, a PE ratio of 27.58 and a beta of 0.48. The stock has a 50 day moving average of $6.80 and a 200 day moving average of $6.09. Bausch Health Cos Inc. has a 52-week low of $4.25 and a 52-week high of $9.85. The company has a debt-to-equity ratio of 141.90, a current ratio of 1.31 and a quick ratio of 0.98.

Bausch Health Cos (NYSE:BHC - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.97 by ($0.07). Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%.The company had revenue of $2.57 billion for the quarter, compared to analysts' expectations of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Bausch Health Cos Inc. will post 4.41 EPS for the current year.

Insider Activity

In other Bausch Health Cos news, Director John Paulson acquired 34,721,118 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were bought at an average price of $9.00 per share, for a total transaction of $312,490,062.00. Following the completion of the transaction, the director owned 70,755,869 shares of the company's stock, valued at approximately $636,802,821. This represents a 96.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired a total of 44,316,834 shares of company stock valued at $369,628,560 in the last quarter. Company insiders own 19.97% of the company's stock.

Analyst Ratings Changes

Separately, Wall Street Zen raised Bausch Health Cos from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat, Bausch Health Cos currently has a consensus rating of "Hold" and a consensus target price of $9.00.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.